The AmoyDx® HRD Complete Panel is an advanced development of the AmoyDx® HRD Focus Panel, which is already established in many laboratories for determining homologous recombination deficiency (HRD).
In both NGS assays, in addition to the BRCA1/2 mutational status, genomic instability is determined based on 24,000 SNPs, which are evenly distributed throughout the genome. The AmoyDx® HRD Complete Panel can be further used to detect SNVs, InDels and homozygous deletions in 20 genes involved in homologous recombination repair (HRR).
Please find a detailed description of the AmoyDx® HRD Complete Panel here.
This product is for research use only (RUO)
The new AmoyDx® BRCA Pro Panel is an improved version of the AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit. Both kits enable analysis of the entire coding regions of the BRCA1 and BRCA2 genes, and of exon/ intron boundries in DNA from FFPE specimen and from peripheral whole blood.
PRAME (PReferentially-expressed Antigen in MElanoma) was first described in a paper by Ikeda et al., through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. [1, 2]